AICAR (50mg)

AICAR (50mg) is a lyophilized research peptide synthesized, purified, and lyophilized in the USA. Each production batch is purified by repeated rounds of reverse-phase HPLC and identity-confirmed by mass spectrometry.

AICAR (50mg) is commonly included in metabolic research panels investigating appetite-regulating pathways and energy homeostasis in laboratory models.

Studies evaluating AICAR (50mg) typically focus on receptor activation profiles and downstream metabolic signaling under controlled in-vitro conditions.

Researchers using AICAR (50mg) often combine dose-response assays with stability testing to establish reproducible experimental baselines.

Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with AICAR (50mg). Summaries are provided for orientation only and reflect the cited sources.

AMPK and PPARdelta agonists are exercise mimetics^[1] — This landmark study investigated whether AMPK and PPARδ agonists could mimic the effects of exercise. The authors report that AICAR, as an AMPK activator, induces exercise-like changes in skeletal muscle. These findings positioned AICAR as a research tool in exercise physiology. (Cell 2008)

Administration of AICAR, an AMPK Activator, Prevents and Reverses Diabetic Polyneuropathy (DPN) by Regulating Mitophagy^[2] — This study examined the effects of the AMPK activator AICAR in models of diabetic polyneuropathy (DPN). The authors report that AICAR administration prevents and reverses the condition, with a proposed mechanism involving regulation of mitophagy. The findings suggest a potential therapeutic application for AICAR in diabetic nerve damage. (International journal of molecular sciences 2024)

Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR^[3] — This study examined the activity of LKB1 and AMPK-related kinases in skeletal muscle under different conditions. The authors compared the effects of muscle contraction, phenformin, and AICAR on these signaling pathways. The results help define how AICAR activates AMPK signaling in muscle. (American journal of physiology. Endocrinology and metabolism 2004)

Metabolic modulators of the exercise response: doping control analysis of an agonist of the peroxisome proliferator-activated receptor δ (GW501516) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR)^[4] — This paper discusses AICAR as a metabolic modulator of the exercise response in the context of doping control analysis. The authors consider both the PPARδ agonist GW501516 and AICAR as substances of interest to anti-doping science. The work reflects the regulatory attention given to exercise-mimetic compounds. (Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 2014)

References

1. Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM. "AMPK and PPARdelta agonists are exercise mimetics." Cell. 2008. pubmed.ncbi.nlm.nih.gov/18674809/
2. Chandrasekaran K, Choi J, Salimian M, Hedayat AF, Russell JW. "Administration of AICAR, an AMPK Activator, Prevents and Reverses Diabetic Polyneuropathy (DPN) by Regulating Mitophagy." International journal of molecular sciences. 2024. pubmed.ncbi.nlm.nih.gov/39795939/
3. Sakamoto K, Göransson O, Hardie DG, Alessi DR. "Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR." American journal of physiology. Endocrinology and metabolism. 2004. pubmed.ncbi.nlm.nih.gov/15068958/
4. Pokrywka A, Cholbinski P, Kaliszewski P, Kowalczyk K, Konczak D, Zembron-Lacny A. "Metabolic modulators of the exercise response: doping control analysis of an agonist of the peroxisome proliferator-activated receptor δ (GW501516) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR)." Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2014. pubmed.ncbi.nlm.nih.gov/25179079/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.